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1. Introduction  
Age-related macular degeneration (AMD) causes a high incidence of morbility in the 
elderly. The dry forms of the disease are the most usual, but wet forms (15% of the total of 
cases) are responsible for 80% of AMD-related cases of severe vision loss. Age-related 
macular degeneration is essentially a choroidal/retinal pigment epithelium (RPE) disease 
which affects the overlying neurosensory retina. Formation of choroidal neovessels that 
penetrate the subretinal space is the main cause of vision loss. Knowing what role the 
vascular endothelial growth factor (VEGF) plays in angiogenesis of the formation of these 
neovessels is a determining factor. Ferrara’s studies describe the four main biological 
functions in VEGF agents (Ferrara & Gerber, 2001): 
1. Increase in vascular permeability 
2. Growth and proliferation of vascular endothelial cells 
3. Migration of vascular endothelial cells 
4. Survival of immature endothelial cells by preventing apoptosis  
Since the formation of choroidal neovascularization (CNV) is a determining factor in vision 
loss in wet AMD, it is reasonable to expect a reduction in the risk of vision loss by inhibiting 
new vessel formation and preventing their growth. The efficacy of antiangiogenesis agents 
for this purpose has provided proof of the concept of therapy targeted at a specific 
molecular step in the process, namely the inhibition of VEGF (Gragouas et al. 2004). 
Therefore the appearance of antibodies against VEGF (anti-VEGF) brought about a 
considerable advance in the treatment of exudative forms of AMD. The most important 
effects are regression of existing vessels, normalization of surviving vessels, and inhibition 
of vessel growth. 
Antiangiogenesis agents have proved to be beneficial but are often administered late in the 
process when the aim of the treatment is to salvage vision rather than to prevent vision loss. 
One obstacle in developing a single approach to treatment stems from the possibility that 
AMD is the product of multiple pathologic processes. A more exciting goal is halting the 
process at a subclinical stage or preventing the disease in patients identified as being at risk 
for vision loss. Progress in isolating multiple processes responsible for disease progression is 
creating new opportunities for combination therapies. 
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2. Composition of neovessels  
Histopathologic examination of CNV shows granulation-like tissue, with the invasion of not 
only blood vessels, but also inflammatory and mesenchymal cells embedded in a loosely 
formed extracellular matrix. Although the majority of damage attributed to CNV is due to 
neovessel bleeding or leakage, there are other components and factors associated with CNV 
that influence the visual prognosis decisively.  
A two-component model of CNV has been developed to offer a conceptual framework to 
structure combination treatments. One is the vascular component, which is composed of 
vascular endothelial cells and associated pericytes. The other is the nonvascular component 
which is made up of the remaining cells, such as the inflammatory cells, glial cells, 
myofibroblasts, and fibrocytes (Spaide, 2006a, 2009). Inhibiting one has the potential to 
inhibit, at least partially, the other due to mutual interactions between the two components 
and each component can potentially cause damage. Inhibiting either one would seem to 
offer some hope in slowing down or arresting the process, but inhibition of both would 
intuitively lead to the best theoretical outcome. 
Blocking the vascular component is achieved mainly by administering anti-VEGF agents, 
although in advanced lesions with mature neovessels covered by pericytes, anti-VEGF on 
their own cannot make these neovessels regress. In these cases, a combination of other 
therapies has to be resorted to which act by means of selective mechanisms, such as blocking 
the platelet-derived growth factor (PDGF) to target the pericytes, or a non-selective attack 
mechanism, such as ionizing radiation which is explained further on (Jain RK, 2005) in this 
chapter.  
 
Fig. 1. CNV components: vascular and nonvascular components 
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Fig. 2. Phases in angiogenesis in which the formation of a neovessel guided by the 
extracellular matrix is shown (Genentech image). 
Blocking the extravascular component, like inhibiting subretinal fibrosis, can considerably 
reduce the morbility of the disease. Biological therapies mediated by cytokines, such as the 
tumor necrosis factor, ionizing radiation which does not only act on the vascular component 
but also on the extravascular component, corticosteroid drugs combined with anti-VEGF 
can improve the therapeutic response, inhibiting the development of the extracellular matrix 
which, in the long term, often plays a determining role in vision loss.  
Currently, the most relevant therapy available is VEGF inhibition.  Possibly, greater success 
could be achieved if other key factors in pathogenesis were also inhibited. It would be more 
advantageous if angiogenesis, scarring, and inflammation were targeted simultaneously. 
Combination approaches may not only increase overall efficacy but also reduce the potential 
for side effects by allowing relatively low doses to yield a greater level of efficacy than 
higher doses of a single agent. 
3. Limitations of anti-VEGF in CNV treatment 
The appearance of anti-VEGF is a revolutionary treatment in wet AMD as, for the first time, 
the progression of the disease can be stopped. Nevertheless, it cannot restore vision and 
there are still many cases that progress in spite of repeated treatment with anti-VEGF. Listed 
below are several limitations of anti-VEGF that make the quest for other therapies, or a 
combination of therapies, necessary. 
3.1 Anti-VEGF agents do not affect mature vessels 
As described above, one of the functions of VEGF is favoring the survival of endothelial 
cells, but this function is just restricted to immature vessels in which angiogenesis 
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necessarily requires the activation of survival pathways to maintain the condition of the 
vessels (Gerber et al., 1998). Nonetheless, the mechanisms involved in the maturing process 
of the vessels, such as pericyte coverage and the formation of interaction between 
endothelial and periendotherlial cells with the basal membrane, free the endothelial cell 
from the requirement of the survival function of VEGF.  
 
Fig. 3. Composition of a mature blood vessel, made up of endothelial cells, pericyte 
coverage, and the interactions between them.  
 
Fig. 4. When the factors that inhibit angiogenesis predominate over those that induce it, two 
things can occur, depending on the context. If the vessel is mature, it will show no response 
as it is quiescent and is not affected by the effect of the antiangiogenic drugs. However, if 
the vessels are immature, with no pericyte coverage, the angiogenesis inhibitors will favor 
apoptosis and the regression of the vessel. When proangiogenic factors predominate the 
immature vessel survives and stabilizes.  
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In this way, the angiogenic factors basically act as survival factors, while antiangiogenic factors 
act as apoptosis-inducing factors in the context of endothelial expansion, which is an immature 
endothelium. Thus the balance between the inducing and inhibiting factors determines the 
destiny of immature vessels, but they do not bear an influence on mature vessels that are in a 
quiescent state due to the interaction between endothelial cells, pericytes, and the extracellular 
matrix (Jimenez Cuenca B, 2003). Therefore, if the neovessels are already mature, they will not 
react to VEGF, nor will they respond to anti-VEGF (Benjamin et. al., 1999). This fact underpins 
the value of combined therapies like photodynamic therapy (PDT) with verteporfin, which is 
necessary to destroy the architecture of different mature components of the neovascular 
membrane that do not respond to anti-VEGF. 
3.2 Anti-VEGF agents do not decrease the CNV size 
Despite their beneficial clinical effects in AMD, anti-VEGF therapies are ineffective in 
regressing existing lesions. Endothelial cells and pericytes that form the structure of new 
vascular tissue typically do not regress with VEGF inhibition alone. This limitation is 
confirmed by data from the key prospective, randomized clinical trials with Ranibizumab, 
such as PIER, ANCHOR, and MARINA (Regillo et al., 2008; Brown et al., 2006; Rosenfeld et 
al., 2006) which did not produce any significant evidence of neovascular regression despite 
improvement in visual acuity. There are no changes from baseline in the CNV area. This 
lack of regression is also consistent with experimental models in which monotherapy with 
anti-VEGF agents inhibits new vascular formation but has little effect on existing capillaries.  
Despite the importance of VEGF agents in the cascade of events that stimulates and sustains 
new vascular formation, VEGF inhibition may have limited effects on existing neovascular 
tissue once subsequent molecular events are triggered, making inhibition of additional 
molecular steps essential to build on the benefits of anti-VEGF therapies. 
3.3 Tachyphylaxis 
Recent publications refer to the possible existence of tachyphylaxis after use of intravitreal 
Bevacizumab. Forooghian and co-workers describe a decrease in the duration of the 
beneficial effect, and even a lack of response, after a mean of eight intravitreal injections 
(Forooghian et al., 2009) in six (n = 59) patients with AMD treated with Bevacizumab in 
monotherapy. 
Currently, the existence of tachyphylaxis is under discussion and its mechanism is 
unknown. This author poses the possibility of an autoimmune mechanism after a patient, 
suffering from uveitis, presented tachyphylaxis immediately after intravitreal injection. It 
must be remembered that Bevacizumab, in spite of being a “humanized” antibody for 
decreasing immunogenicity, could trigger the formation of new anti-Bevacizumab 
antibodies after repeated treatments; this hypothesis has yet to be studied. 
In addition, it should be considered that always inhibiting the same vascular pathway may 
potentiate other pathogenic pathways, such as the inflammatory pathway, or that it may 
increase other cytokines involved in wet AMD. Certainly, a greater inflammatory activity 
and a proliferation of macrophages in the membranes that were surgically extracted with 
prior Bevacizumab treatment were observed compared with those extracted without prior 
intravitreal treatment (Tatar et al., 2009). 
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Furthermore a better response to intravitreal corticoids has been observed in patients who 
stop responding to anti-VEGF intravitreal injections (Schaal et al., 2008). Therefore we pose a 
future problem regarding the use of anti-VEGF, i.e., how to avoid this occurrence. One of 
the most appropriate options would be to find the way to reduce the number of intravitreal 
injections in the treatment of AMD and, to date, the only way is with combined therapies. 
3.4 Anti-VEGF agents do not act on fibrosis and atrophy 
Long-term follow-up of patients who participated in the initial studies of anti-VEGF 
therapies suggests that late visual loss is often caused by processes that seem to be 
independent of neovascularization, particularly fibrosis and atrophy. Although more 
effective antiangiogenesis treatments, including combination strategies, for better blockade 
of new vessel formation are likely to improve outcome, it is appropriate to expand targets to 
other pathophysiologic processes associated with AMD. It is necessary to incorporate 
therapies that block fibrosis and inhibit atrophy or other pathophysiologic processes not 
directly related to neovascularization.  
In Ranibizumab trials (Rosenfeld et al., 2006; Brown et al., 2006), protection against visual 
loss was highly significant relative to controls during a follow-up of twelve and 24 months. 
Gains in visual acuity were much smaller: only 34% achieved >15 letter gain at twelve 
months or 24 months on the most effective dose of Ranibizumab  and 65% of patients with 
very modest gains, no gains, or visual loss over the course of these studies. The subgroup of 
patients with a loss of three or more lines of visual acuity tended to have better visual acuity 
than average at baseline, but a larger area of CNV and a larger area of CNV leakage. Over 
the course of treatment, these patients had a greater growth in total lesion area and more 
retinal pigment epithelium abnormalities.  
 
Fig. 5. (A) Retinograph and OCT of subretinal fibrosis of an AMD patient treated with anti-
VEGF. (B)  Autofluorescence of macular atrophy in the context of wet AMD that had already 
been treated. In both cases, the evolution of visual acuity was poor despite inactivating the 
lesion with repeated doses of anti-VEGF. 
A B 
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In a study in which 82 patients, treated with Ranibizumab  monotherapy, were monitored in 
a follow-up of two to six years, reported that the rate of fibrosis was 50% and the rate of 
atrophy of the retinal pigment epithelium was 40%; 8% percent had both. The fibrosis may 
have been caused by ongoing inflammation and by maturation of vascular tissue. 
Hemorrhage above or below the subretinal pigment epithelium may have played a 
contributing role. Fibrosis was often observed after several years of antiangiogenesis 
therapy even among responders (Kaiser PK, 2009c). 
These findings reinforce other evidence that fibrosis may be an important additional target to 
expand or preserve the benefits of Ranibizumab and other VEGF inhibitors in the treatment of 
AMD. Several strategies are being pursued. These include antagonists of integrin, inhibitors of 
the mammalian target of rapamycin, vascular disrupting agents, and radiation. Control of 
atrophy, which is generally observed at an earlier stage of AMD progression than fibrosis, is 
another potential target for improving outcome. The candidate targets for preventing atrophy 
include neurotrophic factors, free radical scavengers, and retinol binding competitors. 
Complement inhibition may be another viable strategy (Heier JS, 2009).  
3.5 Several pathogenic pathways involved 
Even the maximum inhibition of VEGF does not stop vascular growth due to the presence of 
redundant signaling pathways. Controlling one pathway, the inhibition of 
neovascularization is relatively modest due to the presence of redundant signaling 
pathways. The combination of molecules inhibit different parts of the angiogenic process 
and provide more profound inhibition of neovascularization relative to blocking a single 
proangiogenic signal (Frielander, 2009). 
When one of two inhibitors of angiogenesis was used in experimental studies (Dorrell et al., 
2007) complete inhibition of new vessel formation was achieved in a small proportion of 
animals. In contrast, complete inhibition of neovascularization was observed in more than 
half of the animals treated with triple combination therapy. 
3.6 Route of administration, number and frequency of doses  
Transscleral and intravitreal injections are alternative methods of local delivery. These 
methods may reduce the risk of systemic absorption, because topical therapy results in a 
significant amount of the drug draining away from the eye through the nasal lacrimal duct 
into the gut. Transscleral and intravitreal injections may also increase the percentage of the 
dose that reaches a posterior target. The efficacy of this approach is well documented with 
antiangiogenic therapies for AMD, but it is not risk-free for the patient, and moreover, it 
requires surgical administration, which in many cases can cause saturation of operating 
rooms and delays to the detriment of the patient. Moreover, as it is a chronic disease, 
retreatment is often necessary which increases these problems. Association of anti-VEGF 
with other therapies can be useful in reducing the number of anti-VEGF doses without 
reducing its effectiveness.  
Not least important is the potential for unwanted effects on the biologic function controlled 
by drug targets, such as prolonged suppression of a complex molecule like VEGF, which 
while being a key factor in causing CNV associated with AMD, also plays an important role 
as a neuroprotectant in the mature retina. 
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Exudative AMD is a sub-acute process. Its natural progress from the first symptoms of CNV 
to scar formation takes over a year in most cases, but can even be active for years (Holz et 
al., 2004). In fact, the disease evolves to final subfoveal scarring, including the cases where 
the disease was extrafoveal initially. A well-known fact is that unfortunately, sometimes 
after years of thermal laser treatment of an extrafoveal lesion, there is foveal recurrence. 
Antiangiogenic drugs can prevent the growth of new blood vessels but it is not known how 
long antiangiogenic activity must be kept up to prevent CNV reactivation; it may be needed 
for years.  
There is good justification for considering combination strategies in AMD to build on the 
initial success achieved with VEGF inhibitors, but combination strategies impose 
considerable challenges. The frequency of intravitreal injections causes significant 
difficulties in terms of clinical management and patient convenience and available devices 
for implantation do not seem to be viable for chronic treatment in their current form. 
4. Combined therapies with anti-VEGF 
Mediation synergies are used in medicine to potentiate the effect that two or more drugs 
provide separately, acting on the disease from a different etiopathogenic approach. As AMD 
is a complex process, it seems logical to focus its treatment from different 
physiopathological strategies. The combination of agents with different action mechanisms 
can give rise to a synergic effect, a lower number of overall treatments, and a greater 
duration of the response when compared with Ranibizumab monotherapy, while the 
outcome on visual acuity persists. 
4.1 Action mechanisms: PDT and anti-VEGF 
Photodynamic therapy with verteporfin has been used for years in the treatment of CNV in 
AMD and its action mechanism has been described repeatedly. Briefly, the action of 
verteporfin with non-thermal laser in the macular area where the CNV is present triggers 
processes that lead to apoptosis (Granville et al., 2001), alters the lipids of the cellular 
membranes of the endothelium, triggers plaquetary aggregation and thrombosis, and 
increases vascular permeability, blood stasis, and tissue hypoxia (Fingar, 1996). There is an 
increase in VEGF expression in this process which is the cause of the growth and 
reactivation of the common membrane before the third month; association of an anti-VEGF 
inhibits this effect. 
Pharmacologic inhibition of VEGF-A decreases the proliferation of endothelial cells and 
recruitment of others, such as leukocytes, which can express the cytokines and proteases 
necessary to develop and maintain neovessels (Witmer, 2003; Ferrara, 2003). However, once 
neovascularization is stabilized, it will not respond to anti-VEGF treatment (Benjamin, 1999). 
This would explain the added benefit of associating PDT to destroy the architecture of the 
different components of the neovascular membrane that do not respond to anti-VEGF. 
In 2003, Schmidt-Erfurth evaluated the impact PDT has on the expression and distribution 
of VEGF, VEGF receptor (VEGFR)-3, and pigment epithelium-derived factor (PEDF) after 
applying it to the retina. Said author reported that PDT using verteporfin induces a 
reproducible angiogenic response in elderly human eyes. Vascular endothelial growth 
factor, VEGFR-3, and PEDF expression is enhanced after PDT. Choroidal endothelial cells 
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appear to be the primary site of angiogenic stimulation (Schmidt-Erfurth et al., 2003). This 
suggests that combining PDT with anti-VEGF for decreasing the PDT response is advisable. 
The increase in the formation of VEGF, VEGF-3, and PEDF can favor the growth of CNV 
after initial PDT treatment. This has been observed constantly in our series of 262 cases 
treated with PDT with a 48-month follow-up. We noted an increase in the CNV size 
throughout the observation period. This growth was nearly 60% of the total size increase at 
month three after the first PDT treatment (Mataix et al. 2009). 
Photodynamic therapy is very effective in the initial control of CNV because it achieves 
almost 100% closure of the neovessels in all patients in a period of seven days to one month 
(Miller et al., 1999). Its side effects include hypoxia, stimulation of inflammatory factors, and 
upregulation of VEGF expression (Schmith-Erfurth et al., 2001), which can be prevented by 
associating an anti-VEGF. Although monotherapy with PDT achieves inactivation of the 
lesion, it does not inhibit subsequent growth, bringing about a loss of vision that in many 
cases is difficult to recover (Awan, et al., 2009).  
The benefits of PDT are documented in a great variety of cases with CNV due to AMD and 
there is encouraging evidence of improved outcomes when this angioocclusive modality is 
combined with antiangiogenic agents (Schmidt-Erfurth et al., 2009). It is known that 
treatment with verteporfin produces hypoperfusion in the treated area and that concomitant 
use of anti-VEGF can prolong this effect. Moreover, numerous analyses show minimal 
evidence that there is association with visual deterioration or other adverse effects. 
Furthermore, hypoperfusion helps to reduce recanalization of CNV and permits neuronal 
recovery by decreasing exposure to oxygen and oxidative radicals. The reduced need for 
frequent retreatments clearly has a major appeal due to the lower costs associated with 
fewer interventions and reduced burden of clinical monitoring and diagnostic reevaluations 
(Schmidt-Erfurth et al., 2009). 
4.2 Clinical trials combining PDT + Ranibizumab  
Various clinical assays have been performed with different designs in which combined 
treatment has been compared with monotherapy. A previous study - PROTECT (Schmidt-
Erfurth, 2008) – evaluated the safety and efficacy of administering PDT and Ranibizumab on 
the same day. Photodynamic therapy was applied and an hour later the intravitreal injection 
was given. Photodynamic therapy was repeated every three months in accordance with the 
investigator’s opinion and Ranibizumab was administered the first three months, then as 
required. The study served to show that combined treatment performed on the same day is 
safe and effective.  
The FOCUS study (Heier, 2006) was designed to evaluate, in wet AMD with predominantly 
classic CNV the safety and efficacy of the combination of Ranibizumab and PDT as the first 
treatment, followed by monthly Ranibizumab for the first twelve months and PDT every 
three months according to the investigator’s opinion. The control group only received PDT 
and a simulation injection. After twelve months, the study group showed 90.5% of eyes had 
lost less than 15 letters as opposed to 67.9% in the control group. The combined treatment 
group received a mean of 1.32 PDT and the control group 4 PDT per year the first year. 
After 24 months there was a difference of 12.4 letters in favor of the combined treatment 
group. 
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The most interesting assays are the SUMMIT with its two groups, the DENALI which was 
carried out in the United States and Canada, and the MONTBLANC which was performed 
in Europe. They were designed to determine whether PDT combined with Ranibizumab 
was better than monotherapy with Ranibizumab and they included patients with all types 
of lesions. They were divided randomly into two groups in the MONTBLANC study: in 
one, PDT was performed and basal intravitreal Ranibizumab and two more injections of 
Ranibizumab were administered; subsequent treatments were as required and PDT was 
associated in accordance with the investigator’s opinion every three months. Monotherapy 
and simulating PDT were used in the control group. In the American group, a third group 
with combined treatment of low fluence PDT was added.  
According to the results after twelve months of the MONTBLANC study presented at the 
European Retina Society in Amsterdam in 2010, the differences between combined and 
monotherapy treatment were slight in overall terms. The visual behavior was similar 
between the study and control groups. Neither was there a very significant difference 
regarding the need for retreatments in the two groups, although with combination therapy a 
tendency towards a decrease in repeated treatments with Ranibizumab was observed. After 
twelve months, the mean change in best-corrected visual acuity (BCVA) was +2.5 in the 
combined treatment group and +4.4 in the monotherapy group. Over 50% of the patients in 
the two groups gained at least one line of vision compared with their basal value. There was 
a mean improvement in VA of +2 letters in the combined group and +1.6 letters in the 
monotherapy group after twelve months in the predominantly classic lesions. Patients with 
≤2 area of disc (AD) lesions experienced a mean improvement in VA of +9.7 letters in the 
combination group and +7.1 letters in the monotherapy group after twelve months.  
The patients in the combination group received, on average, 0.3 times fewer Ranibizumab 
injections. The mean number of treatment repetitions with Ranibizumab after the loading 
phase in the combination group was 1.8 compared with 2.2 in the Ranibizumab 
monotherapy group. A tendency towards a decrease in repeated treatments with Lucentis 
was observed in the combination group. Patients with predominantly classic lesions and 
smaller lesions who received combined treatment seemed to present better visual results 
with combined treatment than with monotherapy. It was also observed that the 
monotherapy group conserved the vision obtained after the initial three loading injections 
when these were followed by individualized therapy and, on average, fewer injections were 
necessary. 
In the RADICAL (Reduced Fluence Visudyne-Anti-VEGF-Dexamethasone In Combination for 
AMD Lesions) study, other combinations, as opposed to monotherapy, were analyzed which 
included PDT with reduced fluence + Ranibizumab, PDT with reduced fluence + 
Ranibizumab + dexamethasone, and PDT  with very reduced fluence + Ranibizumab + 
dexamethasone. In general, there was a tendency to fewer repetitions in the combined 
groups, with similar outcomes and adverse effects in all the groups (Hughes et al., 2009).  
4.3 Other studies 
Several studies have been published in which combination treatments were used. Most of 
them were made up of small groups or with short follow-ups. An interesting study by 
Augustin’s group (2007) included 104 eyes; a triple treatment of PDT, dexamethasone, and 
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Bevacizumab intravitreal injections was used. The mean improvement obtained was 1.8 
lines in almost ten months with a low number of retreatments. A vitrectomy was associated 
to inject a greater volume of liquid. In a record of cases published recently, 1,073 patients 
were treated with PDT and Bevacizumab as required, with 1.6 PDT and three injections in 
twelve months, achieving 82% of patients with a loss of fewer than three lines (Kaiser, 
2009a).  
An increase in the treatment-free interval was observed in the PDT + anti-VEGF 
combination. Wan (Wan et al., 2010) in their study on 174 patients with AMD treated with 
PDT followed by intravitreal injection of Bevacizumab, obtained a mean of 193 days of 
treatment-free interval, and 52% of the patients did not require postinduction retreatment in 
the ten months of follow-up. Moreover, other studies report stabilizing the lesion with one 
single dose of PDT induction + anti-VEGF after twelve months follow-up. The percentage of 
cases varies in different studies ranging from 39.6% to 46% to 48% (Mataix, 2010; Navea 
2009; Smith, 2008).  
A systematic review published recently (Das et al., 2011) establishes that intravitreal 
treatment with anti-VEGF obtains an increase in vision in AMD patients. Combination with 
PDT brings about a reduction in the number and frequency of retreatments and maintains 
the improvement in the long term. It seems fairly conclusive that combined treatment for 
neovascular AMD is a therapeutic option for diseases which do not respond to 
monotherapy. Moreover, it has the advantage of minimizing the risk monotherapy does 
have, that of potentiating other chronification pathways of the neovascular disease as it 
could allow compensatory stimulation of other pathogenic mechanisms of the disease. Tao 
and Jonas used a combination of Bevacizumab and high-dose-triamcinolone-acetonide in a 
group of 29 patients who were being treated with Bevacizumab in monotherapy and 
obtaining no visual or anatomic response. They achieved a visual improvement and 
reduction in macular thickness (Tao & Jonas, 2010). However, Rudinsky reported finding no 
benefit in combination therapy in a retrospective study which compared 139 eyes treated 
with Bevacizumab with 236 treated with PDT + Bevacizumab. The monotherapy eyes 
showed an improvement of 5.05 letters versus 4.8 letters with combination therapy; there 
was no difference between the groups. The monotherapy eyes received 3.32 injections 
versus 3.14 injections in the combination therapy group (Rudinsky et al., 2010).  
A recent study (Forte et al., 2011) compared PDT + dexamethasone + anti-VEGF 
(Ranibizumab or Bevacizumab) triple therapy with Ranibizumab or Bevacizumab 
monotherapy. Sixty-one eyes were included in the first group and 40 in the second. The 
mean follow-up was between 14 and 16 months. The triple-therapy group required fewer 
treatments (1.92 vs 3.12); furthermore, on average, this group took longer to require the first 
retreatment (5.4 vs 3.6 months). There was a significant improvement in vision and foveal 
thickness in both groups, therefore it can be concluded that triple therapy reduces the 
number of retreatments when compared with anti-VEGF monotherapy. 
Use of reduced-fluence PDT in combination with anti-VEGF is another method that is 
obtaining good outcomes. Spielberg treated 27 cases with reduced-fluence PDT followed by 
intravitreal Ranibizumab on the same day. Retreatments administered with Ranibizumab 
during the 24-month follow-up stabilized 84% of the patients’ vision or improved it at 
month 24 (Spielberg & Leys, 2010). A prospective comparative study was performed on 85 
AMD patients divided into two groups, one treated with intravitreal Bevacizumab (IVB) 
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monotherapy and the other with IVB combined with low-fluence PDT (300 mW/cm2 for 83 
s, 25 J/cm2 ) with a twelve-month follow-up. The combination of IVB with low fluence PDT 
for the treatment of classic or predominantly classic neovascular AMD worked in a 
synergistic fashion with a significant reduction in IVB reinjection rate (Costagliola et al., 
2009).  
Kovacs recently published a retrospective analysis of triple combination therapy with IVB, 
posterior sub-tenon’s triamcinolon acetonide and low fluence verteporfin PDT with good 
visual results and a reduction in macular thickness with a twelve-month follow-up (Kovacs 
et al., 2011). 
4.4 Our experience 
Our group has considerable experience in treatment combining PDT with anti-VEGF. In 
2006 we began to treat patients with wet AMD using this method. A sample of this work 
appears in two publications showing the results of two groups using different treatments, 
one PDT + Bevacizumab and the other PDT + Ranibizumab. 
The study groups included patients with active subfoveal and juxtafoveal CNV secondary to 
AMD, naïve cases, initial BCVA ≥ 20/400, and maximum lesion size under 5.400 µm defined 
on fluorescein angiography (FA).  
The treatment included a single, initial dose of PDT + Bevacizumab/Ranibizumab. Criteria 
for retreatment were based on OCT, BCVA, and FA; an increase in central retinal thickness 
of over 100 μm or the presence of subretinal fluid was a criterion for retreatment. Loss of 
more than five letters of vision since the previous visit or the presence of new macular 
bleeding was also a criterion for retreatment if any kind of fluid was present on the OCT. In 
both situations an FA was performed and treatment with PDT + 
Bevacizumab/Ranibizumab was provided if a CNV increase or fluorescein leakage was 
observed. If the FA did not show a CNV increase or fluorescein leakage, treatment was 
provided with Ranibizumab alone. Photodynamic treatment was only provided when over 
three months had elapsed since the previous PDT. If development of macular atrophic 
changes seemed to be the cause of vision loss, it was not treated. 
We studied 53 eyes of 53 patients treated with PDT +  Ranibizumab and 63 eyes of 63 
patients treated with PDT + Bevacizumab, with a twelve-month follow-up. The 
demographic characteristics and the characteristics of the CNV were similar in both groups. 
The CNV localization was mainly subfoveal in both groups, with a mean size of 2386 and 
2064 μm in the Ranibizumab and Bevacizumab groups, respectively. 
Evolution of retinal thickness: The OCT baseline central retinal thickness was 372 μm. It 
decreased to 251 μm in the first month of treatment and remained the same throughout the 
follow-up, reaching a mean thickness of 254 μm twelve months later in the group with the 
Ranibizumab combination, with a mean reduction of -118 μm. The OCT baseline central 
retinal thickness was 357 μm, decreasing to 246 μm in the first month of treatment and 
reaching a mean thickness of 227 μm twelve months later in the group with the 
Bevacizumab combination, with a mean reduction of -129 μm. Separate analysis of the two 
groups with Student’s t-test showed the reduction in retinal thickness was statistically 
significant (p<0.05) from the first month, remaining the same throughout the year.  
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 N 
Follow-up 
(months) 
Treatment 
Loss < 15 
letters 
Gain ≥ 25 
letters 
VA 
change 
from 
baseline 
Number of 
treatments  
(average) 
MARINA 240 12 
Ranibizumab 0,5 
mg. (monthly) 
94,6 % 33,8 % +7,2 13 Ranibizumab 
ANCHOR 146 12 
Ranibizumab 0,5 
mg. (monthly)
96,4% 40,3% +11,3 13 Ranibizumab 
PROTECT 32 4 
PDT + 
Ranibizumab 
0,5mg monthly 
96,9%   
1 PDT 
4 Ranibizumab 
FOCUS 106 12 
PDT + 
Ranibizumab 
0,5mg monthly  
90,5% 23,8% +4,9 
1,4 PDT 
13 Ranibizumab 
MONT 
BLANC 
122 12 
PDT + 
Ranibizumab (3 
initial doses) 
retreatments as 
required
87% 18% +2,5 
1,7 PDT 
4,8 
Ranibizumab 
RADICAL 43 12 
PDT (1/2 fluence) 
+ Ranibizumab 
0,5mg (3 initial 
doses) 
retreatments as 
required
88% 26% +5  
Navea et. al. 63 12 
PDT + 
Bevacizumab 
1,25mg (single 
initial doses) 
retreatments as 
required 
95,2% 19% +5,7 
1,46 PDT 
2 Bevacizumab 
Mataix et. al. 53 12 
PDT + 
Ranibizumab 
(single initial 
doses) 
retreatments as 
required 
92,3% 32,7% +7,2 
1,22 PDT 
2,37 
Ranibizumab 
Kaiser et. al. 701 12 
PDT + 
Ranibizumab 
(single initial 
doses) 
retreatments as 
required 
82% 36% +6 
1,6 PDT 
3,2 
Bevacizumab 
Rudinsky et. 
al. 
236 12 
PDT + 
Bevacizumab 
  +4,8 
3,14 
Bevacizumab 
Spielberg et. 
al. 
27 12 / 24 
PDT (1/2 fluence) 
+ Ranibizumab 
0,5mg (3 initial 
doses) 
retreatments as 
required 
84% (24 
months) 
16% (24 
months) 
+7,2 (24 
months) 
5,1 
Bevacizumab 
(12 months) 
7,1  
Bevacizumab 
(24 months) 
Table 1. Summary of studies with  PDT + Anti-VEGF 
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Visual Acuity Evolution: In the Ranibizumab group, the mean initial BCVA was 8.26 lines 
which increased to 10.3 lines in the first month of treatment. This gain was maintained until 
the sixth month, after which it decreased slightly to 9.72 lines twelve month later, thus 
obtaining a mean increase of 1.21 lines, which is equivalent to a gain of 6.05 letters after 
twelve months. This slight decrease is due to the severe and occasional loss of vision in a 
few cases after the sixth month which affected the total mean. The mean initial BCVA was 
8.41 lines in the Bevacizumab group and increased from the first month of treatment to 9.38 
lines. This gain was maintained throughout the twelve months, undergoing small variations 
and reaching 9.54 lines, obtaining a mean increase of 1.12 lines after twelve months, which is 
a gain of 5.6 letters. The percentage of cases that lost 15 letters was 95.2% in the PDT + 
Bevacizumab group and 92.3% in the PDT + Ranibizumab group. Visual gain was 58.7% and 
57.7%, respectively (Figures 6, 7). 
 
Fig. 6. Percentage of visual acuity variations throughout the follow-up in patients treated 
with PDT + Bevacizumab: 95.2% of cases lost fewer than 15 letters after twelve months. 
Visual loss was avoided in 79.3% of cases and 58.7% gained vision. 
The distribution of the lines of vision between the beginning and end of the follow-up is 
statistically significant (p-value <0.001) in both groups. The Mann-Whitney test concludes 
that the visual gain is significantly better (p-value <0.05) in the first six months in the 
Ranibizumab group, but there were no differences between the two groups after one year. 
Retreatments: A record of the number of treatments was kept throughout the study for both 
groups. The patients in the group treated with Bevacizumab received a mean of 1.46 
therapies and 1.92 intravitreal injections, and those treated with Ranibizumab received a 
mean of 1.23 therapies and 2.38 intravitreal injections. The Mann-Whitney test showed that 
the Bevacizumab group received significantly more therapies (p-value <0.05), but there was 
no difference in the number of intravitreal injections. In 21 cases (39.6%) only a single initial 
combination therapy was required in the Ranibizumab group versus 29 cases (46%) in the 
Bevacizumab group to keep the lesion stable until the end of the follow-up. In the 
Ranibizumab group, 77.4% of the patients were treated with a maximum of three injections 
and 79.2% of the patients needed a single PDT treatment at the initiation of the treatment. In 
the Bevacizumab group, 87.3% and 61.9% of the patients were treated, respectively.  
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Fig. 7. Percentage of visual acuity variations throughout the follow-up in patients treated 
with PDT + Ranibizumab: 92.3% of cases lost fewer than 15 letters after twelve months. 
Visual loss was avoided in 78.8% of cases and 57.7% gained vision.  
 
Fig. 8. Evolution of OCT from the beginning of the treatment until the end of the follow-up 
twelve months later. 
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Our results suggest that a combination of PDT and anti-VEGF is a good option for treating 
CNV in AMD more effectively by maintaining good visual results and decreasing the need 
for retreatments. 
5. Other therapies 
The etiology of AMD is multifactorial and there are several mechanisms that can lead to 
irreversible loss of vision. To achieve a complete therapy for CNV, we should not simply 
focus on neovessels, but rather act on both the vascular component (mature and immature 
vessels) and the non-vascular component (inflammatory cells, cytokines, glial cells, 
myofibroblasts, fibrocytes, etc.). 
5.1 The vascular component (immature and mature vessels) 
The antiangiogenesis agents currently used in the treatment of AMD inhibit VEGF by 
blocking the growth factor in the extra-cellular space, thereby preventing access to its 
receptor. Several VEGF inhibitors, including Bevacizumab and Ranibizumab, have 
demonstrated excellent safety and efficacy in exudative AMD (Rosenfeld PJ et al., 2006; 
Spaide RF et al., 2006b). The current strategy of blocking VEGF in the extracellular space 
may be an inadequate approach for long-term control of AMD. Combining drugs that act at 
different points of the angiogenesis pathway has the potential to build on the benefits of 
extracellular VEGF inhibitors, but a more profound inhibition of the disease process may 
require activity in additional pathways of the disease. 
VEGF Trap-Eye is a fully human soluble VEGF receptor fusion protein that binds all forms of 
VEGF-A along with the related placental growth factor (PlGF). VEGF Trap-Eye is made by 
fusing two different domains from VEGF receptors 1 and 2 onto a human Fc fragment. VEGF 
Trap-Eye has tighter VEGF binding than the natural receptor and has greater affinity than the 
current VEGF inhibitors (Steward & Rosenfeld, 2007). Two parallel Phase 3 trials have been 
developed in patients with wet AMD (VIEW 1 and VIEW 2). VEGF Trap-Eye is being dosed at 
0.5 mg every four weeks, 2 mg every four weeks, and 2 mg every eight weeks in direct 
comparison with Ranibizumab administered at 0.5 mg every four weeks during the first year 
of the studies. The primary endpoint was statistical non-inferiority in the proportion of 
patients who maintained (or improved) vision over 52 weeks compared to Ranibizumab. A 
generally favorable safety profile was observed for both VEGF Trap-Eye and Ranibizumab.  
Small interfering RNA agents, such as RTP-801i and Bevasiranib, which turn off target 
genes, are extremely promising in a variety of therapeutic areas. Bevasiranib is designed to 
block the production of VEGF directly by inhibiting the messenger RNA from the VEGF 
gene. Studies in mice have demonstrated that Bevasiranib can inhibit and regress ocular 
neovascularization (Reich et al., 2003). Studies in rabbits have shown that an intravitreal 
injection of Bevasiranib achieved good distribution in the retina and in RPE (Dejneka NS et 
al., 2008). The agent is well distributed after intravitreal injection and well tolerated by 
human subjects (Karagiannis & El-Osta, 2005). A Phase 3 Clinical Trial tests this agent in 
combination with Ranibizumab because potentially the drug may prevent further 
production of VEGF while Ranibizumab blocks the VEGF that is present. 
Experimental models show that monotherapy with anti-VEGF agents inhibits new vascular 
formation but has little effect on existing capillaries. Pericyte coverage provides survival 
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signals to neovascular endothelial cells and hence makes them resistant to VEGF (Bergers et 
al., 2003). Pericytes are essential in vascular maturation so their inhibition is important in 
inhibiting neovascularization and the regression of new mature vessels. Anti-PDGF 
(Platelet-derived growth factor) treatment strips away pericytes to leave the endothelial 
cells unprotected and vulnerable to anti-VEGF treatment (Erber R. et al., 2004). The 
combination of anti-VEGF and anti–PDGF produces inhibition and regression of corneal 
and choroidal neovascularization compared with anti-VEGF treatment alone. In models of 
pathologic tumor angiogenesis, strategies involving both anti-VEGF and anti-PDGF have 
also produced regression when an anti-VEGF therapy alone failed (Jo N et al., 2006). 
Platelet-derived growth factor, which has an important role in recruiting the pericytes 
critical to maturation of vessel walls, may also be a viable target to augment the effects of a 
VEGF inhibitor. A recent phase 1 clinical trial with anti-PDGF (E10030) included patients 
with subfoveal CNV who received three monthly doses of E10030 in combination with a 
standard dose of Ranibizumab. The preliminary findings reveal a reduction in neovascular 
size (neovascular regression) in all patients. This regression is associated with a marked 
improvement in visual acuity, gain ≥ 15 ETDRS letters: 4 weeks (32%) 12 weeks (59%) and 
gain in numbers of letters: 4 weeks (10.9%) 12 weeks (14%). However, it is not yet clear 
whether the improvement was due to the E10030/Ranibizumab combination or simply a 
Ranibizumab effect (Boyer DS et al., 2009). 
The inhibition of Insulin-like growth factor could be another option in the treatment of 
neovessels. It leads to endothelial cell proliferation and inhibits apoptosis of endothelial 
cells, the nicotinic acetylcholine receptor, which also induces endothelial cell migration, and 
tubular binding proteins, which govern endothelial cell shape formation.  
5.2 The nonvascular component (inflammatory cells, cytokines, glial cells, 
myofibroblasts, and fibrocytes) 
Antiangiogenesis agents are effective for preventing progression of CNV in a substantial 
proportion of patients, although regression is not typically observed. Experimental studies 
indicate that newly formed capillaries are no longer susceptible to regression with anti-
VEGF agents within about two weeks after formation. Antiangiogenesis agents may still be 
effective for preventing the development of additional capillaries or reducing leakage in 
vessels invading the retina, but the persistence of CNV may stimulate inflammation or other 
pathologic processes that eventually result in vision loss due to the formation of fibrosis. 
Prevention of fibrosis is essential to the preservation of VA.  
Radiation therapy has long been used to control fibrosis in a variety of tissues. In AMD, 
radiation may be particularly attractive because there is evidence of synergistic inhibition of 
neovascularization when radiation is combined with antiangiogenesis drugs (Nieder C. et 
al., 2007). Historically, radiation monotherapy sufficient to eradicate CNV effectively has 
been associated with a modest benefit for AMD. The growing evidence that antiangiogenic 
agents can increase the antitumor efficacy of radiotherapy includes studies in animal 
models: the combination of radiation and antiangiogenesis agents had a greater effect in 
reducing tumor regrowth than either alone (Gorski DH et al., 1999). In another animal 
study, the use of anti-VEGF and anti-PDGF agents in combination with radiation showed a 
significantly greater antitumor effect relative to radiation alone (Timke C et al., 2008). 
Mammalian target of rapamycin (mTOR) inhibitors (Sirolimus) radiosensitize cancer cells in 
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vitro and several studies have demonstrated their ability to radiosensitize in vivo (Shinohara 
ET et al., 2005). In a Phase I recent report, CNV was irradiated in a few patients with 
strontium 90 delivered by a specialized, 20-gauge, intravitreal probe that is placed over the 
lesion intraoperatively. All patients underwent a vitrectomy before radiotherapy and were 
treated with Bevacizumab before and after radiation. In a 4-minute exposure, the estimated 
dose at the lesion was 24 Gy. Results were excellent, with 76% of patients gaining at least 10 
letters of visual acuity. Most of the responders required no more than one additional 
injection of Bevacizumab over the first year of follow-up.  
Integrins as a mediator of adhesion both between cells and between cells and extracellular 
matrix, have a role in a variety of proliferative processes, including fibrosis. Integrin also 
seems to have a direct influence on proliferative kinase signalingare, a mediator of adhesion 
between cells and extracellular matrix. It is a transmembrane protein that binds to 
extracellular matrix proteins (fibronectin) allowing cell adhesion and cytoskeletal 
organization. The ǂ5ǃ1 is especially important in pathologic angiogenesis (not in normal 
vasculature) (Kim S et al., 2000). Many of the cellular effects of VEGF are duplicated 
downstream in the angiogenic cascade by the interaction between the transmembrane 
integrin ǂ5ǃ1receptor and its natural ligand, fibronectin. In addition to VEGF, the 
interaction of integrin ǂ5ǃ1 with fibronectin is critical to endothelial cell survival. Integrin 
ǂ5ǃ1 has been shown to be upregulated in all the cells associated with AMD pathogenesis, 
including endothelial cells, retinal pigment epithelium cells, macrophages, and fibroblasts. 
This implicates this molecule in multiple pathogenic processes involved in AMD, including 
neovascularization, vascular leakage, and inflammation (Klatt K et al., 2007). Two studies 
have demonstrated that once neovascular tissue begins to grow, the extracellular matrix 
needs to adhere to the neovascular endothelial cells for them to survive (Hynes RO, 2002; 
Hodivala-Dilke et al., 2003). Inhibiting the ligation of integrin ǂ5ǃ1 and fibronectin may 
disrupt the process of neovascularization, regardless of the upstream growth factor 
pathway. Volociximab (M200), a chimeric monoclonal antibody targeting integrin ǂ5ǃ1 to 
block its ligation of fibronectin, has robustly inhibited human umbilical vein endothelial cell 
tube formation in laboratory tests. It does so regardless of an initial growth factor stimulant. 
It has also inhibited neovascularization in primate choroid tissue and tumor angiogenesis in 
rabbits (Ramakrishnan V et al., 2006; Bhaskar V et al., 2008).  
Vascular disrupting agents also have potential for the inhibition of fibrosis as well as 
formation of new blood vessels. Unlike antiangiogenesis agents that block formation of new 
blood vessels, vascular-disrupting agents attack newly formed endothelium by disrupting 
connectivity between cells. This activity is expected to be complementary to anti-VEGF 
agents because it takes place at a later stage of neovascularization. It may also exert an 
important antifibrotic effect. A vascular-disrupting agent called combretastatin A4P (CA4P) 
has been evaluated in a Phase 1 study in humans with myopic macular degeneration, where 
it demonstrated relatively modest effects, but the characteristics of AMD may be more 
suitable for its activity. 
Compared with age-matched controls, individuals with AMD demonstrate elevations in a 
variety of systemic biomarkers of inflammation, including activated monocytes and 
interleukin-6 (Vine AK et al., 2005 & Seddon et al., 2005). An increased risk of AMD in 
individuals with polymorphisms in their genes coding for the complement regulatory proteins 
is another signal that complement driven inflammation is perhaps an important mediator of 
this disease (Klein RJ et al., 2005). Although terminal elements of the complement pathway are 
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implicated in the formation of drusen in primate models and human postmortem specimens 
(Anderson DH et al., 2002), patients with membranoproliferative glomerulonephritis type II, a 
disorder characterized by uncontrolled complement cascade activation, develop drusen 
histologically identical to drusen associated with AMD (Mullins RF et al., 2001). These findings 
support the potential for adding therapies directed at complement activation to those that 
already demonstrate activity in AMD, but it is not yet clear what incites the complement 
cascade or how to inhibit it at its source. Therefore, to attack the complement pathway, it may 
be necessary to address both membrane attack complex and C5a, while preserving the 
beneficial antimicrobial function of C3 (Giese MJ et al., 1994). There are numerous questions 
about where and when to block complement to inhibit best progression of AMD. An 
experimental treatment, known as ARC 1905, has been associated with the inhibition of C5a 
and C5b-9. In experimental models, this inhibitor of C5aR has demonstrated measurable 
activity in reducing the influx of neutrophils and macrophages and has also been associated 
with suppression of CNV (Adamis AP, 2009).  
Mammalian target of rapamycin, a protein kinase linked to a variety of gene transcriptions 
and protein production, including VEGF, is strongly implicated in a number of proliferative 
processes and is a targetable mediator of fibrosis. Palomid 529 (mTOR inhibitor) has 
demonstrated a strong antifibrotic effect in retinal fibrosis models, including laser-induced 
retinopathy. The antifibrotic activity of this inhibitor has been measured, across a variety of 
endpoints, including inhibition of the inflammatory response as well as the extent of the 
fibrotic scar. Other mammalian targets of rapamycin inhibitors, such as sirolimus, have 
demonstrated good antiangiogenic, antiinflammatory, and antifibrotic effects (Chiang GC et 
al., 2007) and inhibit the response to interleukin-2 (IL-2) and thereby block activation of T- 
and B-cells.  
6. Conclusion 
The potential for a single therapy to control the complex process of AMD seems to be 
relatively remote. It is not clear that a combination of different agents, working on the same 
pathway of extracellular VEGF inhibition, will reduce AMD progression, but there may be a 
strong potential for additive or synergistic effects from combining drugs with independent 
mechanisms. The current strategy of blocking VEGF in the extracellular space may be an 
inadequate approach for long-term control of AMD. Combining drugs that act at different 
points of the angiogenesis pathway has the potential to build on the benefits of extracellular 
VEGF inhibitors, but a more profound inhibition of the disease process may require activity 
in additional pathways of the disease. 
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